Back to results
US 2019/0054091 A1Published application
Prophylactic agent and/or therapeutic agent for diffuse large b-cell lymphoma
AssigneeOno Pharmaceutical Co., Ltd.
InventorsToshio YOSHIZAWA, Ryohei KOZAKI
Life of this patent
Estimating the term…
Abstract
To provide a medicament which shows more remarkable effect in treatment of activated B-cell like diffuse large B-cell lymphoma (ABC-CLBCL) than the existing Btk inhibitor, and is excellent in safety. The present compound exhibits more remarkable effect in treatment of activated B-cell like diffuse large B-cell lymphoma (ABC-DLBCL) patients, inter alia, ABC-DLBCL patients having CD79B wild-type gene background than the existing Btk inhibitor, and therefore, it can attain the object of the present invention.
Claims14
1-11. (canceled)
A method of treating B-cell non-Hodgkin's lymphoma comprising:
- administering to a human in need thereof a pharmaceutically effective amount of 6-amino-9-[(3R)-1-(2-butynoyl)-3-pyrrolidinyl]-7-(4-phenoxyphenyl)-7,9-dihydro-8H-purin-8-one or a salt thereof and at least one additional anticancer agent;
- wherein the at least one additional anticancer agent comprises a PI3K inhibitor.
Dependencies are inferred from the claim text.